Investors will look for updates from management on any delay in supply and manufacturing or timeline of some clinical studies due to potential disruptions from the COVID-19 pandemic when the company reports.Key Recent Development  Earlier this month, Biogen completed submission of the biologics license application (BLA) to the FDA, seeking approval of aducanumab for Alzheimerâ€™s disease.